How the product works:
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, reduces glucagon levels, slows gastric emptying, and decreases appetite, leading to improved blood glucose control and metabolic balance.
Who it is recommended for:
Clinical studies and evidence:
Tirzepatide has been extensively studied in the global SURPASS clinical trial program. These studies demonstrated significant reductions in HbA1c levels and improved glycemic outcomes compared with standard therapies, confirming its efficacy and safety profile.
Indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. The medication lowers fasting and postprandial blood glucose levels and supports metabolic regulation.
Administered as a subcutaneous injection once weekly in the abdomen, thigh, or upper arm. One prefilled pen provides four doses, covering one full month of treatment. Dosage regimen should be determined by a healthcare professional.
Contraindications
Side effects
